Richter Syndrome: From Molecular Pathogenesis to Druggable Targets

Medicine and Dentistry

• B-Cell Chronic Lymphocytic Leukemia 100%
• B Lymphocyte Receptor 100%
• Molecular Pathology 100%
• Clinical Trial 66%
• Diffuse Large B-Cell Lymphoma 66%
• Personalized Medicine 66%
• Aggressive Lymphoma 66%
• Medicine 33%
• T Cell 33%
• Programmed Cell Death 33%
• Cell Cycle 33%
• Cytotoxicity 33%
• Monoclonal Antibody 33%
• Rituximab 33%
• Cell Proliferation 33%
• Survival Rate 33%
• Leukemia 33%
• Cancer 33%
• Xenograft 33%
• Hyperactivation 33%
• Chemoimmunotherapy 33%
• Autoantigen 33%
• Cancer Inhibition 33%
• Programmed Death-Ligand 1 33%
• DNA Damage Response 33%
• Cyclin Dependent Kinase Inhibitor 2A 33%
• Immune Checkpoint Inhibitor 33%
• Antibody Conjugate 33%
• Systemic Juvenile Idiopathic Arthritis 33%
• Diseases 33%
• Protein Kinase B 33%

Keyphrases

• Druggable Targets 100%
• Molecular Pathogenesis 100%
• Richter Syndrome 100%
• Chronic Lymphocytic Leukemia 25%
• Aggressive Lymphoma 16%
• Molecular Targets 16%
• Precision Medicine 16%
• Unmet Medical Need 16%
• Bcl-2 Inhibitor 16%
• Clinical Trials 8%
• C-Myc 8%
• Genetic Lesions 8%
• Tumor Protein p53 (TP53) 8%
• Diffuse Large B-cell Lymphoma (DLBCL) 8%
• Monoclonal Antibody 8%
• Small Molecules 8%
• Leukemia 8%
• Altered Expression 8%
• T Cells 8%
• Notch1 8%
• Survival Rate 8%
• Pathologic 8%
• Targeted Therapeutics 8%
• Molecular Mechanism 8%
• Non-covalent 8%
• Innovative Approach 8%
• Pathway Inhibitors 8%
• Vulnerability 8%
• B-cell Receptor Signaling 8%
• Aggressive Disease 8%
• De Novo Diffuse Large B-cell Lymphoma 8%
• B Cell Receptor 8%
• Anti-CD20 Antibody 8%
• Autoantigen 8%
• Molecular Features 8%
• AKT Pathway 8%
• Hyperactivity 8%
• Apoptotic Cells 8%
• DNA Damage Response 8%
• Novel Therapeutics 8%
• Immune Checkpoint 8%
• Cyclin-dependent Kinase Inhibitor 2A (CDKN2A) 8%
• Stereotyped B-cell Receptors 8%
• Chemoimmunotherapy 8%
• Molecular Investigation 8%
• Notch1 Signaling 8%
• Tumor Suppression 8%
• Molecular Profile 8%
• Early Phase Clinical Trials 8%
• Immunoconjugate 8%
• Programmed Death-ligand 1 (PD-L1) 8%
• Immune Checkpoint Inhibitors 8%
• Secondary Malignancy 8%
• ROR1 8%
• Medicine Therapy 8%
• Mouse Xenograft Model 8%
• Resistance to Cytotoxicity 8%
• Direct Transformation 8%
• BTK Inhibitor 8%
• Overreactivity 8%
• Treatment Refractoriness 8%